Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer ; volume:12 ; number:1 ; day:28 ; month:2 ; year:2012 ; pages:1-12 ; date:12.2012
BMC cancer ; 12, Heft 1 (28.2.2012), 1-12, 12.2012

Urheber
Magbanua, Mark Jesus M.
Beteiligte Personen und Organisationen
Sosa, Eduardo V.
Scott, Janet H.
Simko, Jeff
Collins, Colin
Pinkel, Dan
Ryan, Charles J.
Park, John W.
SpringerLink (Online service)

DOI
10.1186/1471-2407-12-78
URN
urn:nbn:de:1111-201603045450
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:36 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Magbanua, Mark Jesus M.
  • Sosa, Eduardo V.
  • Scott, Janet H.
  • Simko, Jeff
  • Collins, Colin
  • Pinkel, Dan
  • Ryan, Charles J.
  • Park, John W.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients

Ureter metastatic castration-resistant prostate cancer: a case report

Ureter metastatic castration-resistant prostate cancer: a case report

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management

Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)

Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer

Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer

Verbundene Objekte